1. It is important for the provider to maintain a high index of suspicion for those at risk for tumor lysis syndrome (TLS), which includes a large tumor burden, high proliferation rate, pre-existing kidney dysfunction and certain types of cancer such as Burkett lymphoma and acute leukemias.

2. The best form of treatment includes preventive measures with aggressive hydration and urate-lowering agents.

3. In established TLS, in addition to hydration, the use of rasburicase and correction of any electrolyte derangements are key to present complications and preserve renal function.

4. A coordinated approach between the oncologist, nephrologist, and critical care specialists is required to provide effective management.

5. Educating patients and caregivers about the signs and symptoms of TLS is important for early detection and prompt treatment, especially in outpatient settings.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to viral gastroenteritis (rotaviruses, noroviruses, caliciviruses, adenoviruses, sapoviruses, astroviruses). It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to Prion disease (CJD, vCJD). It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to rotaviruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to human coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to Toxoplasma gondii. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HIV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to rabies virus. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HSV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to human CMV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter provides details of the viruses and other organisms that are more severe in immunocompromised patients (HIV, CMV, EBV, HSV, VZV, HHV6, HHV7, HHV8, adenoviruses, influenzaviruses, parainfluenzaviruses, RSV, SARS-CoV-2, HBV, HEV, polyomaviruses, papillomaviruses, parvovirus, T gondii). It gives details of symptoms, diagnosis, treatment and strategies for reducing the risk of severe symptoms.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to influenza viruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to parainfluenzaviruses. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HAV. It provides information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to VZV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to RSV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter provides details of the different kinds of vaccines available (live, attenuated, killed, inactivated, recombinant, subunit, mRNA, DNA and vector) for virus infections (e.g. SARS-CoV-2, HAV, HBV, influenzaviruses, JEE, measlesvirus, mumpsvirus, rubellavirus, HPV, rabies, polio, rotavirus, smallpox, mpox, yellow fever virus) in humans. It details the routes of administration and usage (e.g. pre-exposure or post-exposure, childhood, occupational health, travel and for at-risk groups).

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to chlamydia (C.trachomatis, C.pneumoniae, C. psittaci, C. abortus, LGV). It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.

This chapter details the epidemiology, route of spread, prevalence, incubation period and at-risk groups relating to HTLV. It gives information on symptoms, laboratory diagnosis, treatment, prophylaxis and infection control.